Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

Clinical Uses of Mycophenelate Mofetil and Cyclosporin A in Patients after Liver Transplantation

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Application of Immunosuppressant Protocol with Low Concentration of Cyclosporine A in Patients with Renal Transplantation

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Two Different Doses of Cyclosporine for Patients After Renal Transplantation:Clinical Controlled Study

The Use of CsA after Combined Liver-Intestine Transplantation

Combined Use of MMF with Low Dosage of Cyclosporine A in Renal Transplantation

The Clinical Value of Enzyme-Multiplied Immunoassay Technique Monitoring the Plasma Concentrations of Cyclosporine A after Renal Transplantation.

Assessment of Cyclosporine A Withdrawal in Renal Allograft Transplant Recipients

Monitoring the peak value of ciclosporin A blood drug level in patients after liver transplantation

A Meta-Analysis of Therapeutic Effect of Cyclosporine Microemulsion and Tacrolimus for Patients Undergoing Liver Transplantation

Tacrolimus and cyclosporine A combined with mycophenolate mofetil influence on the plasma mycophenolic acid concentration

Clinical Analysis on Conversion from Tacrolimus to Cyclosporine A in Recipients of Liver Transplantation

Low‐dose ciclosporin mizoribine and prednisolone in renal transplantation: A new triple‐drug therapy

Preliminary investigation of monitoring whole blood concentration of cyclosporine A in the patients after allogeneic renal transplantation

Correlation Factors Influencing Blood Concentration of Ciclosporin A in Patients Underwent Liver Trans Plantation

Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China

Effects of Immunosuppressants on CD+ CD25+ Regulatory T Cells in Human Renal Transplant Recipients

Effects of Cyclosporin A and Coadministration with Methylprednisolone on Human Liver Microsomal Cytochrome P450 3A

Optimal Sampling Time-Point for Cyclosporin A Concentration Monitoring in Heart Transplant Recipients.